Pseudomyxoma peritonei laboratory findings: Difference between revisions
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) |
||
| Line 8: | Line 8: | ||
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref><ref name="pmid15932563">{{cite journal |vauthors=Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B |title=Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence |journal=Colorectal Dis |volume=7 |issue=4 |pages=382–6 |date=July 2005 |pmid=15932563 |doi=10.1111/j.1463-1318.2005.00773.x |url=}}</ref> | The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref><ref name="pmid15932563">{{cite journal |vauthors=Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B |title=Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence |journal=Colorectal Dis |volume=7 |issue=4 |pages=382–6 |date=July 2005 |pmid=15932563 |doi=10.1111/j.1463-1318.2005.00773.x |url=}}</ref> | ||
*Carcinoembryonic antigen ([[CEA]]) | *Carcinoembryonic antigen ([[CEA]]) | ||
*Carbohydrate antigen 19 | *Carbohydrate antigen 19-9 (CA19-9) | ||
*Carbohydrate antigen 125 ([[CA125]]) | *Carbohydrate antigen 125 ([[CA125]]) | ||
Revision as of 14:50, 22 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei laboratory findings On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei laboratory findings |
|
Risk calculators and risk factors for Pseudomyxoma peritonei laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]Parminder Dhingra, M.D. [3]
Overview
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA19.9), carbohydrate antigen 125 (CA125).
Laboratory Findings
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:[1][2]
These tumor markers are useful for postoperative follow-up and prediciton of the completeness of cytoreductive surgery.[1]
References
- ↑ 1.0 1.1 Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M (August 2007). "Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy". Ann. Surg. Oncol. 14 (8): 2300–8. doi:10.1245/s10434-007-9393-9. PMID 17510772.
- ↑ Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B (July 2005). "Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence". Colorectal Dis. 7 (4): 382–6. doi:10.1111/j.1463-1318.2005.00773.x. PMID 15932563.